These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28223103)

  • 1. HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF.
    Jeong JH; Kim J; Hong YS; Kim D; Kim JE; Kim SY; Kim KP; Yoon YK; Kim D; Chun SM; Park Y; Jang SJ; Kim TW
    Clin Colorectal Cancer; 2017 Sep; 16(3):e147-e152. PubMed ID: 28223103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer.
    Santos FA; Reis RM; Barroti LC; Pereira AAL; Matsushita MM; de Carvalho AC; Datorre JG; Berardinelli GN; Araujo RLC
    J Gastrointest Cancer; 2024 Mar; 55(1):344-354. PubMed ID: 37608030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
    Cushman SM; Jiang C; Hatch AJ; Shterev I; Sibley AB; Niedzwiecki D; Venook AP; Owzar K; Hurwitz HI; Nixon AB
    Clin Cancer Res; 2015 Mar; 21(5):1078-86. PubMed ID: 25520391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Metastasectomy in the Multimodality Approach for
    Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A
    Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group.
    Salgado Fernández M; Reboredo López M; Covela Rúa M; Candamio S; González-Villarroel P; Sánchez-Cousido LF; Graña B; Carral-Maseda A; Cameselle-García S; Varela Pose V; Gallardo-Martín ME; Martínez-Lago N;
    Target Oncol; 2024 Jul; 19(4):565-573. PubMed ID: 38780742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification.
    Lee SM; Oh H
    Sci Rep; 2024 May; 14(1):11432. PubMed ID: 38763942
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Battaglin F; Ou FS; Qu X; Hochster HS; Niedzwiecki D; Goldberg RM; Mayer RJ; Ashouri K; Zemla TJ; Blanke CD; Venook AP; Kabbarah O; Lenz HJ; Innocenti F
    J Clin Oncol; 2024 Jun; 42(16):1890-1902. PubMed ID: 38457761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.
    Zhou YW; Zhao X; Ni L; Cao P; Leng WB; Zhu Q; Gou HF; Zhang J; Li XF; Qiu M
    Int Immunopharmacol; 2024 Apr; 131():111887. PubMed ID: 38503018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current advances in targeted therapy for metastatic colorectal cancer - Clinical translation and future directions.
    Johnson D; Chee CE; Wong W; Lam RCT; Tan IBH; Ma BBY
    Cancer Treat Rev; 2024 Apr; 125():102700. PubMed ID: 38422896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
    Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
    EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
    Spiekman IAC; Zeverijn LJ; Geurts BS; Verkerk K; Haj Mohammad SF; van der Noort V; Roepman P; de Leng WWJ; Jansen AML; Gootjes EC; de Groot DA; Kerver ED; van Voorthuizen T; Roodhart JML; Valkenburg-van Iersel LBJ; Gelderblom H; Voest EE; Verheul HMW
    Eur J Cancer; 2024 May; 202():113988. PubMed ID: 38471288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR.
    Lim Y; Kim S; Kang JK; Kim HP; Jang H; Han H; Kim H; Kim MJ; Lee KH; Ryoo SB; Park JW; Jeong SY; Park KJ; Kang GH; Han SW; Kim TY
    Sci Rep; 2021 Aug; 11(1):16333. PubMed ID: 34381078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status.
    Jensen BV; Schou JV; Yilmaz M; Johannesen HH; Skougaard K; Linnemann D; Hogdall EV; Larsen FO; Johansen JS; Pfeiffer P; Nielsen DL
    Int J Cancer; 2021 May; 148(10):2542-2556. PubMed ID: 33336394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients.
    Samalin E; Mazard T; Assenat E; Rouyer M; de la Fouchardière C; Guimbaud R; Smith D; Portales F; Ychou M; Adenis A; Fiess C; Lopez-Crapez E; Thezenas S
    Dig Liver Dis; 2024 Jan; ():. PubMed ID: 38233313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Fisher JG; Tait D; Garrett-Mayer E; Halabi S; Mangat PK; Schink JC; Alvarez RH; Veljovich D; Cannon TL; Crilley PA; Pollock T; Calfa CJ; Al Baghdadi T; Thota R; Fleming N; Cotta JA; Rygiel AL; Warren SL; Schilsky RL
    Target Oncol; 2020 Dec; 15(6):733-741. PubMed ID: 33090333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study.
    Randon G; Nakamura Y; Yaeger R; Lonardi S; Cremolini C; Elez E; Nichetti F; Ghelardi F; Nasca V; Bergamo F; Conca V; Ros J; Bando H; Maddalena G; Oldani S; Prisciandaro M; Raimondi A; Schrock AB; Agnelli L; Walch H; Yoshino T; Pietrantonio F
    Clin Cancer Res; 2024 Jan; 30(2):436-443. PubMed ID: 37610454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.
    Singh H; Sahgal P; Kapner K; Corsello SM; Gupta H; Gujrathi R; Li YY; Cherniack AD; El Alam R; Kerfoot J; Andrews E; Lee A; Nambiar C; Hannigan AM; Remland J; Brais L; Leahy ME; Rubinson DA; Schlechter BL; Meyerson M; Kuang Y; Paweletz CP; Lee JK; Quintanilha JCF; Aguirre AJ; Perez KJ; Huffman BM; Rossi H; Abrams TA; Kabraji S; Trusolino L; Bertotti A; Sicinska ET; Parikh AR; Wolpin BM; Schrock AB; Giannakis M; Ng K; Meyerhardt JA; Hornick JL; Sethi NS; Cleary JM
    Clin Cancer Res; 2024 Apr; 30(8):1669-1684. PubMed ID: 38345769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression.
    Seo AN; Kwak Y; Kim DW; Kang SB; Choe G; Kim WH; Lee HS
    PLoS One; 2014; 9(5):e98528. PubMed ID: 24879338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and prognostic analysis of the cetuximab resistance-related gene
    Zhu N; Fang X; Li D; Yang M; Zhu L; Zhong L; Weng S; Wang J; Yuan Y
    Am J Cancer Res; 2021; 11(6):2769-2781. PubMed ID: 34249427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer.
    Singh H; Kang A; Bloudek L; Hsu LI; Corinna Palanca-Wessels M; Stecher M; Siadak M; Ng K
    JNCI Cancer Spectr; 2024 Jan; 8(1):. PubMed ID: 37815820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.